BMS 954561
Alternative Names: BMS-954561Latest Information Update: 28 Aug 2015
At a glance
- Originator Bristol-Myers Squibb
- Class Analgesics
- Mechanism of Action GABA receptor modulators; Nicotinic receptor modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Diabetic neuropathies; Postherpetic neuralgia
Most Recent Events
- 25 Oct 2011 Bristol-Myers Squibb completes enrolment in its phase II trial for Postherpetic neuralgia in US and France (NCT01305538)
- 28 Apr 2011 Phase-II clinical trials in Diabetic neuropathies in USA (PO)
- 07 Apr 2011 Phase-II clinical trials in Postherpetic neuralgia in France (PO)